Anixa Biosciences
115 articles about Anixa Biosciences
-
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology
6/21/2022
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the publication of a peer-reviewed journal article in Clinical and Experimental Vaccine Research.
-
Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference
5/5/2022
Anixa Biosciences, Inc. today announced that it will present a company update at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 (Hybrid Conference).
-
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
4/28/2022
Anixa Biosciences, Inc. today announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022.
-
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022
4/6/2022
Anixa Biosciences, Inc. today announced that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at The 4th International Workshop on CAR-T (iwCAR-T) 2022 on Friday, April 29, 2022.
-
Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center
3/30/2022
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer.
-
Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC
3/17/2022
Anixa Biosciences, Inc. announced that the Company will present at the 2022 Virtual Growth Conference, hosted by M-Vest, a division of Maxim Group LLC, on March 28th – 30th from 9:00 am – 5:00 pm EDT.
-
Currently, women with breast and ovarian cancers have limited treatment options. Anixa Biosciences, ImmunoGen and IMV are working to change that.
-
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine
1/25/2022
Anixa Biosciences, Inc. today announced that the Japanese Patent Office has issued a Decision to Grant of a patent to Cleveland Clinic titled, "Ovarian Cancer Vaccines."
-
Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor
1/24/2022
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the company and its partner, MolGenie GmbH, have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting Mpro, the main protease of the SARS-CoV-2 virus.
-
Oh, Where Vaccines Could Take Us
1/12/2022
2021 could very well have been “the year of the vaccine.” While this modality is certainly not new, the COVID-19 pandemic is sparking excitement about just what else they might be able to do. -
CEO to CEO: Tips for First-time Founders
1/11/2022
BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders. -
Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference
12/16/2021
Anixa Biosciences, Inc. today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7 , 2022.
-
Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant
12/7/2021
Anixa Biosciences, Inc. today announced the results of a genomic variant analysis done with its partner, MolGenie, GmbH, on potential compounds to treat COVID-19.
-
A large number of people were waiting for the breast cancer vaccine. Now, at present, the world has witnessed the first potential vaccine. Let's take a look at it.
-
Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study
10/26/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") announced today that, in conjunction with its partner, Cleveland Clinic, it has commenced dosing of patients for a novel study of its vaccine that is being investigated for preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
-
Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy
10/1/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell,
-
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium
9/14/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), announced today that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at the Antibody Society and Ovarian Cancer Research Alliance's Emerging Immunotherapeutics for Ovarian Cancer Symposium
-
Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/8/2021
Anixa Biosciences, Inc. announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15 , 2021.
-
Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer
9/7/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of Pamela D. Garzone, Ph.D., as Chief Development Officer.
-
Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy
8/30/2021
Anixa Biosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy